Skip to content

Study · Randomized controlled trial · 2017

13 results

Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.

Tsai JN, Jiang LA, Lee H, Hans D, Leder BZ

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry16 Jun 2017Cited by 32 (Europe PMC)

PMID28624340 (opens in a new tab)PMCIDPMC5673584 (opens in a new tab)DOI10.1016/j.jocd.2017.05.007 (opens in a new tab)PepBankPUB-28624340
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, teriparatide increased spine trabecular bone score from baseline.

    In plain wordsIn postmenopausal women with osteoporosis, spine trabecular bone score increased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular bone score with teriparatide
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 moAs given in this study (human).

    Measurements

    TBS change
    2.7%
    teriparatide at 24 mo

    Source sentences

    Summary
    After 24 mo, TBS increased by 2.7 ± 4.7% in the teriparatide group (p = 0.009 vs baseline), by 1.8 ± 5.0% in the denosumab group (p = 0.118 vs baseline), and by 4.5 ± 6.7% in the combination group (p = 0.017 vs baseline), with no significant between-group differences.
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, spine trabecular bone score changes did not differ significantly between teriparatide and denosumab.

    In plain wordsIn postmenopausal women with osteoporosis, spine trabecular bone score changes did not differ significantly between teriparatide and denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTrabecular bone score versus denosumab
    Study

    n: not reported in source

    Comparator
    Denosumab
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 moAs given in this study (human).

    Measurements

    TBS change
    2.7%
    teriparatide at 24 mo
    TBS change
    1.8%
    denosumab at 24 mo

    Source sentences

    Summary
    After 24 mo, TBS increased by 2.7 ± 4.7% in the teriparatide group (p = 0.009 vs baseline), by 1.8 ± 5.0% in the denosumab group (p = 0.118 vs baseline), and by 4.5 ± 6.7% in the combination group (p = 0.017 vs baseline), with no significant between-group differences.
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, adding teriparatide to denosumab did not significantly alter spine trabecular bone score changes versus denosumab alone.

    In plain wordsIn postmenopausal women with osteoporosis, adding teriparatide to denosumab did not significantly change trabecular bone score versus denosumab alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCombination trabecular bone score versus denosumab
    Study

    n: not reported in source

    Comparator
    Denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 moAs given in this study (human).

    Measurements

    TBS change
    4.5%
    combination at 24 mo
    TBS change
    1.8%
    denosumab at 24 mo

    Source sentences

    Summary
    After 24 mo, TBS increased by 2.7 ± 4.7% in the teriparatide group (p = 0.009 vs baseline), by 1.8 ± 5.0% in the denosumab group (p = 0.118 vs baseline), and by 4.5 ± 6.7% in the combination group (p = 0.017 vs baseline), with no significant between-group differences.
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

Studies that did not test the peptide alone10

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, trabecular bone score changes at 48 months did not differ significantly among teriparatide and denosumab sequences.

    In plain wordsIn postmenopausal women with osteoporosis, trabecular bone score changes did not differ significantly among the teriparatide and denosumab sequences.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLong-term trabecular bone score between sequences
    Study

    n = 65

    Comparator
    All treatment sequences
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change from month 0
    5.1%
    teriparatide-to-denosumab at 48 mo
    TBS change from month 0
    3.6%
    denosumab-to-teriparatide at 48 mo
    TBS change from month 0
    6.1%
    combination-to-denosumab at 48 mo

    Source sentences

    Summary
    After 48 mo, compared to month 0, TBS increased by 5.1 ± 5.8% in the teriparatide-to-denosumab group, by 3.6 ± 4.2% in the denosumab-to-teriparatide group, and by 6.1 ± 4.7% in the combination-to-denosumab group (p < 0.001 vs baseline for all groups, p = not significant for between-group differences).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, combined teriparatide and denosumab increased spine trabecular bone score from baseline.

    In plain wordsIn postmenopausal women with osteoporosis, combined teriparatide and denosumab increased spine trabecular bone score from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular bone score with combination
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change
    4.5%
    combination at 24 mo

    Source sentences

    Summary
    After 24 mo, TBS increased by 2.7 ± 4.7% in the teriparatide group (p = 0.009 vs baseline), by 1.8 ± 5.0% in the denosumab group (p = 0.118 vs baseline), and by 4.5 ± 6.7% in the combination group (p = 0.017 vs baseline), with no significant between-group differences.
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, combined teriparatide and denosumab did not significantly alter spine trabecular bone score changes versus teriparatide alone.

    In plain wordsIn postmenopausal women with osteoporosis, combined teriparatide and denosumab did not significantly change trabecular bone score versus teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCombination trabecular bone score versus teriparatide
    Study

    n: not reported in source

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change
    4.5%
    combination at 24 mo
    TBS change
    2.7%
    teriparatide at 24 mo

    Source sentences

    Summary
    After 24 mo, TBS increased by 2.7 ± 4.7% in the teriparatide group (p = 0.009 vs baseline), by 1.8 ± 5.0% in the denosumab group (p = 0.118 vs baseline), and by 4.5 ± 6.7% in the combination group (p = 0.017 vs baseline), with no significant between-group differences.
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, spine trabecular bone score continued increasing after combined teriparatide and denosumab switched to denosumab.

    In plain wordsIn postmenopausal women with osteoporosis, trabecular bone score increased after combined teriparatide and denosumab switched to denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular bone score after combination-to-denosumab switch
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the 6 mo after the treatments were switched (months 24-30), TBS continued to increase in the combination-to-denosumab and teriparatide-to-denosumab groups but decreased by -1.1 ± 4.0% in the denosumab-to-teriparatide group (p < 0.05 vs other groups).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, spine trabecular bone score continued increasing after teriparatide switched to denosumab.

    In plain wordsIn postmenopausal women with osteoporosis, trabecular bone score increased after teriparatide switched to denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular bone score after teriparatide-to-denosumab switch
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In the 6 mo after the treatments were switched (months 24-30), TBS continued to increase in the combination-to-denosumab and teriparatide-to-denosumab groups but decreased by -1.1 ± 4.0% in the denosumab-to-teriparatide group (p < 0.05 vs other groups).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, the denosumab-to-teriparatide sequence decreased trabecular bone score after switching, unlike the combination-to-denosumab sequence.

    In plain wordsIn postmenopausal women with osteoporosis, trabecular bone score decreased after denosumab switched to teriparatide, unlike the combination-to-denosumab sequence.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular bone score after denosumab-to-teriparatide switch versus combination sequence
    Study

    n: not reported in source

    Comparator
    Combination-to-denosumab sequence
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change
    −1.1%
    denosumab-to-teriparatide months 24-30

    Source sentences

    Summary
    In the 6 mo after the treatments were switched (months 24-30), TBS continued to increase in the combination-to-denosumab and teriparatide-to-denosumab groups but decreased by -1.1 ± 4.0% in the denosumab-to-teriparatide group (p < 0.05 vs other groups).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, the denosumab-to-teriparatide sequence decreased trabecular bone score after switching, unlike the teriparatide-to-denosumab sequence.

    In plain wordsIn postmenopausal women with osteoporosis, trabecular bone score decreased after denosumab switched to teriparatide, unlike the reverse sequence.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular bone score after denosumab-to-teriparatide switch versus teriparatide sequence
    Study

    n: not reported in source

    Comparator
    Teriparatide-to-denosumab sequence
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change
    −1.1%
    denosumab-to-teriparatide months 24-30

    Source sentences

    Summary
    In the 6 mo after the treatments were switched (months 24-30), TBS continued to increase in the combination-to-denosumab and teriparatide-to-denosumab groups but decreased by -1.1 ± 4.0% in the denosumab-to-teriparatide group (p < 0.05 vs other groups).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  8. 11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, the teriparatide-to-denosumab sequence increased trabecular bone score from baseline at 48 months.

    In plain wordsIn postmenopausal women with osteoporosis, the teriparatide-to-denosumab sequence increased trabecular bone score from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLong-term trabecular bone score: teriparatide-to-denosumab
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change from month 0
    5.1%
    teriparatide-to-denosumab at 48 mo

    Source sentences

    Summary
    After 48 mo, compared to month 0, TBS increased by 5.1 ± 5.8% in the teriparatide-to-denosumab group, by 3.6 ± 4.2% in the denosumab-to-teriparatide group, and by 6.1 ± 4.7% in the combination-to-denosumab group (p < 0.001 vs baseline for all groups, p = not significant for between-group differences).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  9. 12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, the denosumab-to-teriparatide sequence increased trabecular bone score from baseline at 48 months.

    In plain wordsIn postmenopausal women with osteoporosis, the denosumab-to-teriparatide sequence increased trabecular bone score from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLong-term trabecular bone score: denosumab-to-teriparatide
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change from month 0
    3.6%
    denosumab-to-teriparatide at 48 mo

    Source sentences

    Summary
    After 48 mo, compared to month 0, TBS increased by 5.1 ± 5.8% in the teriparatide-to-denosumab group, by 3.6 ± 4.2% in the denosumab-to-teriparatide group, and by 6.1 ± 4.7% in the combination-to-denosumab group (p < 0.001 vs baseline for all groups, p = not significant for between-group differences).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  10. 13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal osteoporotic women, the combination-to-denosumab sequence increased trabecular bone score from baseline at 48 months.

    In plain wordsIn postmenopausal women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased trabecular bone score from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLong-term trabecular bone score: combination-to-denosumab
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    TBS change from month 0
    6.1%
    combination-to-denosumab at 48 mo

    Source sentences

    Summary
    After 48 mo, compared to month 0, TBS increased by 5.1 ± 5.8% in the teriparatide-to-denosumab group, by 3.6 ± 4.2% in the denosumab-to-teriparatide group, and by 6.1 ± 4.7% in the combination-to-denosumab group (p < 0.001 vs baseline for all groups, p = not significant for between-group differences).
    3 context sentences
    Summary · context
    In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 µg daily), denosumab (60 mg every 6 mo), or both.
    Summary · context
    Then, women originally assigned to 24 mo of teriparatide received 24 mo of denosumab, whereas subjects originally randomized to 24 mo of denosumab received 24 mo of teriparatide.
    Summary · context
    Subjects who received both drugs received an additional 24 mo of denosumab alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.